Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera

Reuters12-08

Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera

Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics, Inc. announced new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera. The results were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition on December 6, 2025. The study demonstrated that rusfertide provided sustained hematocrit control and response, defined by the absence of phlebotomy eligibility, with no new safety signals observed. Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the U.S. Food & Drug Administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001395064-25-000164), on December 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589333230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 19:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589333230","market":"us","top_or_hot":-1,"title":"Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Takeda Pharmaceutical Co. Ltd. and Protagonist <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. announced new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera. The results were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition on December 6, 2025. The study demonstrated that rusfertide provided sustained hematocrit control and response, defined by the absence of phlebotomy eligibility, with no new safety signals observed. Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation from the U.S. Food &amp; Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001395064-25-000164), on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 19:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Takeda Pharmaceutical Co. Ltd. and Protagonist <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. announced new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera. The results were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition on December 6, 2025. The study demonstrated that rusfertide provided sustained hematocrit control and response, defined by the absence of phlebotomy eligibility, with no new safety signals observed. Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation from the U.S. Food &amp; Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001395064-25-000164), on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTGX","symbol_name":"Protagonist Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1HWfBh:1","article_id":"2589333230","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589333230","pubTimestamp":1765192760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics, Inc. announced new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera. The results were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition on December 6, 2025. The study demonstrated that rusfertide provided sustained hematocrit control and response, defined by the absence of phlebotomy eligibility, with no new safety signals observed. Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the U.S. Food & Drug Administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTGX":"Protagonist Therapeutics Inc","BK4139":"生物科技"},"translate_title":"武田和PROTAGONION报告3期研究显示Rusfertide可维持真性红细胞增多症的红细胞压积控制","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":0.9},"content_text":"Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera\n    \n\n        Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics, Inc. announced new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera. The results were presented in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition on December 6, 2025. The study demonstrated that rusfertide provided sustained hematocrit control and response, defined by the absence of phlebotomy eligibility, with no new safety signals observed. Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the U.S. Food & Drug Administration.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001395064-25-000164), on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589333230","isCrawlerRequest":true}